Find out more about our unique therapeutic strategy
Chronic obstructive pulmonary disease (COPD) afflicts more than a quarter of a billion people globally, leading to more than 3 million deaths every year.
There are no clinical trials showing that any existing medications for COPD modify the long-term decline in lung function that characterizes COPD.
Find out more about our unique approach targeting epithelial barrier insufficiency as a key driver of inflammation in chronic respiratory diseases.
EpiEndo Pharmaceuticals attending BIO International Convention in Boston
Dr Kate Hanrott appointed as Director of Clinical Operations and Sciences
EpiEndo Pharmaceuticals to attend SCIENCE4PEACE
Main Office [+354] 454 0095
SEND US A MESSAGE
Thanks for submitting!